NCT00386581View on ClinicalTrials.gov

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

February 28, 2005

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

atomoxetine

DRUG

placebo

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY